Amryt benefits from new specialized commissioning process in England

The UK’s Amryt Pharma (AIM: AMYT) has received a positive reimbursement decision in England for its Lojuxta (lomitapide), as a treatment for homozygous familial hypercholesterolaemia (HoFH).

The decision means that patients will be able to gain access to the therapy through the country’s national healthcare provider, the National Health Service (NHS). Amryt says it expects to start distributing the drug in England before the end of the year.

While reimbursement decisions are usually handled by the UK’s health technology assessor, the National Institute for Health and Care Excellence (NICE), Amryt was able to gain clearance for its orphan drug via a new specialized commissioning process launched by NHS England.